Biologics Safety Testing Market (2026 - 2035)

ID: MRFR/LS/5336-HCR 100 Pages Rahul Gotadki Last Updated: October 27, 2026
Biologics Safety Testing Market Research Report By Testing Type (Sterility Testing, Endotoxin Testing, Bioburden Testing, Validation Testing), By Product Type (Reagents, Kits, Services), By Application (Vaccine Development, Therapeutics, Blood and Blood Products, Cellular and Gene Therapy), By End Use (Pharmaceutical Companies, Biotechnology Companies, Research Institutions) and By Regional (North America, Europe, South America, Asia-Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035
Biologics Safety Testing Market
Market Size
Forecast Period2026-2035
CAGR (2026-2035)10.90%
2025 Market SizeUSD 4.30 Billion
2035 Market SizeUSD 12.08 Billion
Key Players
Charles River Laboratories
Merck KGaA
Thermo Fisher Scientific
Lonza Group
Eurofins Scientific
SGS SA
Opportunities
  • Animal-Free and Recombinant Testing Portfolios
  • Emerging-Market Laboratory Networks
  • NGS-Based Adventitious Agent Detection
  1. 1 Market Summary | |
  2. 2 Key Report Takeaways | |
    1. 2.1 By Product & Service | |
    2. 2.2 By Test Type | |
    3. 2.3 By Application | |
    4. 2.4 By End User | |
    5. 2.5 By Region | |
  3. 3 Market Size and Forecast (2021–2035) | |
    1. 3.1 Historical Market Size (2021–2025) | |
    2. 3.2 Forecast Market Size (2026–2035) | |
    3. 3.3 Year-over-Year Growth Analysis | |
  4. 4 Driver Impact Analysis | |
    1. 4.1 Cell and Gene Therapy Pipeline Expansion | |
    2. 4.2 ICH Q5A(R2) Viral Safety Harmonization | |
    3. 4.3 EU GMP Annex 1 Contamination Control Requirements | |
    4. 4.4 Outsourcing of Testing to CDMOs and Contract Labs | |
    5. 4.5 Biosimilar and Monoclonal Antibody Volume Growth | |
    6. 4.6 Adoption of Rapid and Animal-Free Methods | |
    7. 4.7 Asia-Pacific Biomanufacturing Capacity Build-Out | |
  5. 5 Restraints Impact Analysis | |
    1. 5.1 High Capital Cost of Automated and Rapid Platforms | |
    2. 5.2 Shortage of Qualified Microbiologists and Virologists | |
    3. 5.3 Lengthy Validation for Alternative Methods | |
    4. 5.4 Horseshoe Crab Lysate Supply Constraints | |
    5. 5.5 Geopolitical Disruption to Cross-Border Testing | |
  6. 6 Opportunities | |
    1. 6.1 Animal-Free and Recombinant Testing Portfolios | |
    2. 6.2 Emerging-Market Laboratory Networks | |
    3. 6.3 NGS-Based Adventitious Agent Detection | |
    4. 6.4 Data Monetization and QC-as-a-Service Models | |
    5. 6.5 Rapid Release Testing for Autologous Therapies | |
  7. 7 Regional Market Share and Country-Level Analysis | |
    1. 7.1 North America | | |
      1. 7.1.1 US | | |
      2. 7.1.2 Canada | | |
      3. 7.1.3 Mexico | |
    2. 7.2 Europe | | |
      1. 7.2.1 Germany | | |
      2. 7.2.2 UK | | |
      3. 7.2.3 France | | |
      4. 7.2.4 Italy | | |
      5. 7.2.5 Spain | | |
      6. 7.2.6 Nordic Countries | | |
      7. 7.2.7 Russia | | |
      8. 7.2.8 Rest of Europe | |
    3. 7.3 Asia-Pacific | | |
      1. 7.3.1 China | | |
      2. 7.3.2 India | | |
      3. 7.3.3 Japan | | |
      4. 7.3.4 South Korea | | |
      5. 7.3.5 ASEAN | | |
      6. 7.3.6 Rest of Asia-Pacific | |
    4. 7.4 South America | | |
      1. 7.4.1 Brazil | | |
      2. 7.4.2 Argentina | | |
      3. 7.4.3 Rest of South America | |
    5. 7.5 Middle East & Africa | | |
      1. 7.5.1 Saudi Arabia | | |
      2. 7.5.2 UAE | | |
      3. 7.5.3 South Africa | | |
      4. 7.5.4 Egypt | | |
      5. 7.5.5 Rest of MEA | |
  8. 8 Future Outlook (2026–2035) | |
    1. 8.1 Automation and AI in QC Microbiology | |
    2. 8.2 Sequencing-Led Virus Detection | |
    3. 8.3 Animal-Free Compliance as Standard Practice | |
    4. 8.4 Decentralized and Rapid-Release Testing | |
  9. 9 Segmentation Analysis | |
    1. 9.1 By Product & Service | | |
      1. 9.1.1 Products | | |
      2. 9.1.2 Services | |
    2. 9.2 By Test Type | | |
      1. 9.2.1 Sterility Tests | | |
      2. 9.2.2 Endotoxin Tests | | |
      3. 9.2.3 Bioburden Tests | | |
      4. 9.2.4 Cell Line Authentication & Characterization Tests | | |
      5. 9.2.5 Adventitious Agent Detection Tests | | |
      6. 9.2.6 Mycoplasma Tests | | |
      7. 9.2.7 Residual Host Contaminant Detection Tests | |
    3. 9.3 By Application | | |
      1. 9.3.1 Recombinant Protein / Monoclonal Antibodies | | |
      2. 9.3.2 Vaccines & Therapeutics | | |
      3. 9.3.3 Cellular & Gene Therapy | | |
      4. 9.3.4 Blood & Blood Products | | |
      5. 9.3.5 Tissue & Tissue Products | | |
      6. 9.3.6 Stem Cell | |
    4. 9.4 By End User | | |
      1. 9.4.1 Biopharma & Biotech Companies | | |
      2. 9.4.2 CDMOs | | |
      3. 9.4.3 Academic & Research Institutes | | |
      4. 9.4.4 Others | |
  10. 10 Competitive Landscape | |
    1. 10.1 Market Concentration Analysis | |
    2. 10.2 Competitive Benchmarking Table | |
    3. 10.3 Company Profiles | | |
      1. 10.3.1 Charles River Laboratories | | |
      2. 10.3.2 Merck KGaA (MilliporeSigma) | | |
      3. 10.3.3 Thermo Fisher Scientific | | |
      4. 10.3.4 Lonza Group | | |
      5. 10.3.5 Eurofins Scientific | | |
      6. 10.3.6 SGS SA | | |
      7. 10.3.7 Sartorius AG | | |
      8. 10.3.8 bioMérieux | | |
      9. 10.3.9 WuXi AppTec | | |
      10. 10.3.10 Associates of Cape Cod (FUJIFILM Wako) | | |
      11. 10.3.11 Pacific BioLabs | |
  11. 11 Recent News & Developments | |
  12. 12 Report Scope and Methodology | |
  13. 13 Detailed Sources and Citations | |
  14. 14 Frequently Asked Questions (FAQs) | | LIST OF TABLES | |
  15. TABLE 1 Global Market Snapshot – Key Metrics, 2025–2035 | |
  16. TABLE 2 Global Market Size & Forecast, by Revenue (USD Billion), 2021–2035 | |
  17. TABLE 3 Driver Impact Analysis, 2026–2035 | |
  18. TABLE 4 Restraints Impact Analysis, 2026–2035 | |
  19. TABLE 5 Regional Summary, 2025 | |
  20. TABLE 6 North America Market, by Country | |
  21. TABLE 7 Europe Market, by Country | |
  22. TABLE 8 Asia-Pacific Market, by Country | |
  23. TABLE 9 South America Market, by Country | |
  24. TABLE 10 Middle East & Africa Market, by Country | |
  25. TABLE 11 Market Segmentation, by Product & Service | |
  26. TABLE 12 Market Segmentation, by Test Type | |
  27. TABLE 13 Market Segmentation, by Application | |
  28. TABLE 14 Market Segmentation, by End User | |
  29. TABLE 15 Competitive Benchmarking Table, 2025 | |
  30. TABLE 16 Report Scope and Methodology | |
  31. TABLE 17 Detailed Sources and Citations | |
  32. TABLE 18 Segmentation Quick Reference | | LIST OF FIGURES | |
  33. FIGURE 1 Market Dynamics Overview – Drivers, Restraints, and Opportunities | |
  34. FIGURE 2 Industry Value Chain Analysis | |
  35. FIGURE 3 Porter's Five Forces Analysis | |
  36. FIGURE 4 Global Market Size Trend (USD Billion), 2021–2035 | |
  37. FIGURE 5 Market Share, by Product & Service, 2025 | |
  38. FIGURE 6 Market Share, by Test Type, 2025 | |
  39. FIGURE 7 Market Share, by Application, 2025 | |
  40. FIGURE 8 Market Share, by End User, 2025 | |
  41. FIGURE 9 Regional Market Share, 2025 | |
  42. FIGURE 10 Regional Growth Comparison, 2026–2035 | |
  43. FIGURE 11 Competitive Landscape – Estimated Revenue Share Ranges, 2025

Segmentation Quick Reference

DimensionSub-SegmentsDominant SegmentFastest Growing Segment
By Product & ServiceProducts (Reagents & Kits, Instruments), ServicesProducts – 58.2% share (2025)Services – 12.5% CAGR (2026–2035)
By Test TypeSterility Tests, Endotoxin Tests, Bioburden Tests, Cell Line Authentication & Characterization Tests, Adventitious Agent Detection Tests, Mycoplasma Tests, Residual Host Contaminant Detection TestsSterility Tests – 26.6% share (2025)Adventitious Agent Detection Tests – 12.8% CAGR (2026–2035)
By ApplicationRecombinant Protein / Monoclonal Antibodies, Vaccines & Therapeutics, Cellular & Gene Therapy, Blood & Blood Products, Tissue & Tissue Products, Stem CellRecombinant Protein / Monoclonal Antibodies – 29.5% share (2025)Cellular & Gene Therapy – 13.8% CAGR (2026–2035)
By End UserBiopharma & Biotech Companies, CDMOs, Academic & Research Institutes, OthersBiopharma & Biotech Companies – 44.2% share (2025)CDMOs – 13.6% CAGR (2026–2035)
By RegionNorth America, Europe, Asia-Pacific, South America, Middle East & AfricaNorth America – 40.5% share (2025)Asia-Pacific – 12.6% CAGR (2026–2035)

 

Market Segmentation Overview

By Product & Service

Sub-SegmentKey Trend
ProductsReagents & Kits bundled with rFC alternatives; Instruments shifting to automated rapid detection
ServicesIntegrated testing bundled into CDMO manufacturing contracts.

 

Products lead because Reagents & Kits are consumed with every batch released, whether testing happens in-house or at a contract lab. Services grow faster because viral vector and cell therapy testing require BSL-2 containment and validated virology methods that most emerging sponsors cannot justify building themselves. This aligns with the outsourcing momentum described in Section 9.1.

By Test Type

Sub-SegmentKey Trend
Sterility TestsAutomation compressing per-test pricing
Endotoxin TestsTransition from LAL to recombinant reagents
Bioburden TestsExpanded in-process monitoring under Annex 1
Cell Line Authentication & Characterization TestsMaster cell bank qualification for new modalities
Adventitious Agent Detection TestsNGS replacing in vivo assays
Mycoplasma TestsMigration to PCR-based rapid kits
Residual Host Contaminant Detection TestsTighter host-cell protein and DNA limits

 

Sterility Tests hold the largest share because compendial release rules apply to every sterile biologic, even as automated systems reduce labor per test. Adventitious Agent Detection Tests grow fastest, driven by ICH Q5A(R2)'s broader scope and the replication-competent virus risks tied to lentiviral and AAV vectors. Mycoplasma Tests are gaining speed through PCR kits, which support rapid-release needs for autologous therapies.

By Application

Sub-SegmentKey Trend
Recombinant Protein / Monoclonal AntibodiesBiosimilar launches sustaining release volumes
Vaccines & TherapeuticsRegionalized production for WHO prequalification
Cellular & Gene TherapyPatient-specific batch panels raising test intensity
Blood & Blood ProductsPathogen reduction lowering testing frequency
Tissue & Tissue ProductsGrowth in allograft and regenerative products
Stem CellPluripotent line characterization requirements

 

Recombinant Protein / Monoclonal Antibodies lead because antibody plants run high batch volumes, and biosimilar entry adds new products needing full release panels. Cellular & Gene Therapy grows fastest since each autologous dose is its own batch, which multiplies sterility, mycoplasma, and vector safety tests per patient treated. Blood & Blood Products face slower growth as pathogen-reduction technologies reshape screening needs.

By End User

Sub-SegmentKey Trend
Biopharma & Biotech CompaniesIn-house QC retained for commercial supply control
CDMOsBundled manufacturing-plus-testing contracts
Academic & Research InstitutesOutsourcing of complex virology work
OthersCombination product and device testing needs

 

Biopharma & Biotech Companies remain the largest end user because large manufacturers keep routine release testing in-house to protect supply continuity and inspection readiness. CDMOs grow fastest as virtual biotechs buy manufacturing and testing together, and CDMOs spread validation and containment costs across many client programs. Academic & Research Institutes rely on external labs for GMP virology that grant funding cannot support.

 

 

 

 

 

 

 

.

Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.